If our findings can be replicated in additional samples and the mechanism verified in functional analyses, this could motivate inhibitors of P2X7 as the second antipurinergic treatment to reach clinical trials for cardiovascular disease. This evidence concerns the gene P2RX7 and cardiovascular disorder.